Cargando…

Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2

The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopf, Maximilian, Kloos, Christof, Wolf, Gunter, Müller, Ulrich Alfons, Müller, Nicolle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913515/
https://www.ncbi.nlm.nih.gov/pubmed/33546360
http://dx.doi.org/10.3390/jcm10040571
_version_ 1783656819893207040
author Hopf, Maximilian
Kloos, Christof
Wolf, Gunter
Müller, Ulrich Alfons
Müller, Nicolle
author_facet Hopf, Maximilian
Kloos, Christof
Wolf, Gunter
Müller, Ulrich Alfons
Müller, Nicolle
author_sort Hopf, Maximilian
collection PubMed
description The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 ± 0.8 years. The following changes were observed: HbA1c −1.0% ± 1.9 (p < 0.001), eGFR −7.0 mL/min ± 13.3 (p < 0.001), albuminuria −23.9 mg/g creatinine ± 144.5 (p = 0.118), bodyweight −3.0 kg ± 5.8 (p < 0.001), systolic blood pressure −6 mmHg ± 22 (p = 0.01), diastolic blood pressure −2 mmHg ± 14 (p = 0.243). 53 participants continuously applied the therapy. Twenty-eight participants discontinued SGLT-2-inhibitors due to various reasons: 20 participants because of genital- or urinary tract infections. One for dysuria, seven due to reduced eGFR below 45 mL/min. This study showed a considerable reduction of HbA1c and a modest reduction of eGFR, bodyweight and systolic blood pressure under clinical routine conditions. Genital infections occurred markedly more often than in randomized controlled trials. To apply SGLT-2-inhibitors more safely in clinical routine individual risks for genital and urinary tract infections should be considered and re-evaluated during therapy.
format Online
Article
Text
id pubmed-7913515
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79135152021-02-28 Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 Hopf, Maximilian Kloos, Christof Wolf, Gunter Müller, Ulrich Alfons Müller, Nicolle J Clin Med Article The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 ± 0.8 years. The following changes were observed: HbA1c −1.0% ± 1.9 (p < 0.001), eGFR −7.0 mL/min ± 13.3 (p < 0.001), albuminuria −23.9 mg/g creatinine ± 144.5 (p = 0.118), bodyweight −3.0 kg ± 5.8 (p < 0.001), systolic blood pressure −6 mmHg ± 22 (p = 0.01), diastolic blood pressure −2 mmHg ± 14 (p = 0.243). 53 participants continuously applied the therapy. Twenty-eight participants discontinued SGLT-2-inhibitors due to various reasons: 20 participants because of genital- or urinary tract infections. One for dysuria, seven due to reduced eGFR below 45 mL/min. This study showed a considerable reduction of HbA1c and a modest reduction of eGFR, bodyweight and systolic blood pressure under clinical routine conditions. Genital infections occurred markedly more often than in randomized controlled trials. To apply SGLT-2-inhibitors more safely in clinical routine individual risks for genital and urinary tract infections should be considered and re-evaluated during therapy. MDPI 2021-02-03 /pmc/articles/PMC7913515/ /pubmed/33546360 http://dx.doi.org/10.3390/jcm10040571 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hopf, Maximilian
Kloos, Christof
Wolf, Gunter
Müller, Ulrich Alfons
Müller, Nicolle
Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
title Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
title_full Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
title_fullStr Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
title_full_unstemmed Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
title_short Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
title_sort effectiveness and safety of sglt2 inhibitors in clinical routine treatment of patients with diabetes mellitus type 2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913515/
https://www.ncbi.nlm.nih.gov/pubmed/33546360
http://dx.doi.org/10.3390/jcm10040571
work_keys_str_mv AT hopfmaximilian effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2
AT klooschristof effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2
AT wolfgunter effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2
AT mullerulrichalfons effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2
AT mullernicolle effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2